Coya Therapeutics Inc. (COYA)
| Bid | 6 |
| Market Cap | 100.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.98 |
| PE Ratio (ttm) | -6.14 |
| Forward PE | -5.38 |
| Analyst | Buy |
| Ask | 6.92 |
| Volume | 45,735 |
| Avg. Volume (20D) | 91,215 |
| Open | 6.28 |
| Previous Close | 6.54 |
| Day's Range | 6.01 - 6.48 |
| 52-Week Range | 4.75 - 10.24 |
| Beta | 0.32 |
About COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial f...
Analyst Forecast
According to 4 analyst ratings, the average rating for COYA stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 199.00% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must WatchPotential initiation of phase 2b study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in 2025 barring successful IND clearance by the FDA. Biomarker data fro...
